Andrew Baum
Stock Analyst at Citigroup
(2.93)
# 1,643
Out of 5,058 analysts
65
Total ratings
74.42%
Success rate
13.97%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $48 → $45 | $45.79 | -1.73% | 13 | Nov 17, 2025 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $24.88 | +4.50% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $95.05 | +20.99% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $38.65 | +3.49% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $232.91 | -7.69% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $1,049.60 | -14.73% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $5.23 | +91.20% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $46.34 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 17, 2025
Maintains: Neutral
Price Target: $48 → $45
Current: $45.79
Upside: -1.73%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $24.88
Upside: +4.50%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $95.05
Upside: +20.99%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $38.65
Upside: +3.49%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $232.91
Upside: -7.69%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $1,049.60
Upside: -14.73%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $5.23
Upside: +91.20%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $46.34
Upside: -